Immupharma

Company developing Lupuzor a potential treatment for Lupus with US FDA's fast track designation

placeLondon, England, United Kingdom calendar_todayFounded 1999 groups14 employees language immupharma.co.uk

Registered entities

Investor mix

6 investors on record.

Investor typeCountShare
Private equity233%
Bank & private debt117%
Other / undisclosed350%
Coming soon